Isotope Metallomics Quality Assurance Program (IMQAP) Consortium
Compiled by KHAO Editorial — aggregated from 2 sources. See llms.txt for citation guidance.
★ Tier-1 Source
The National Institute of Standards and Technology (NIST) is establishing the Isotope Metallomics Quality Assurance Program (IMQAP) Consortium.
Key facts
- It is estimated that by 2030 the cost of these diseases will reach $47 trillion worldwide (World Economic Forum, 2011)
- World Economic Forum and The Harvard School of Public Health, Methodological Appendix: The Global Economic Burden of Non-communicable Diseases 2013-2020 1st ed
- Eisenhauer, A., Müller, M., Heuser, A., Kolevica, A., Glüer, C.-C., Both, M., Laue, C., Hehn, U.v
- Morgan, J.L.L., Skulan, J.K., Gordon, G.W., Romaniello, S.J., Smith, S.M. and Anbar, A.D., 2012, Rapidly assessing changes in bone mineral balance using natural stable calcium isotopes, PNAS
Summary
Please direct all Consortium questions to imqap nist.gov (imqapnistgov). The use of stable metal isotopes in the health and medical sciences, known as Isotope Metallomics, shows promise for developing clinical biomarkers and improving diagnostics and prognostics. For example, isotopes of Calcium (Ca) found in blood and urine can be utilized to identify musculoskeletal disorders like osteoporosis well in advance of the conventional Dual X-ray absorptiometry (DXA) method (Eisenhauer et al., 2019; 2024). Chronic diseases like diabetes, cardio-vascular diseases, and cancers are the leading cause of death worldwide. It is estimated that by 2030 the cost of these diseases will reach $47 trillion worldwide (World Economic Forum, 2011). The IMQAP Consortium aims to assist its members in improving the methods used to measure metal isotopes in clinical and biological materials.